Vireo Growth (VREOF) Share-based Compensation (2020 - 2026)
Vireo Growth (VREOF) posted Share-based Compensation of $7.0 million for Q1 2026, up 100.87% sequentially from $3.5 million in Q4 2025, and up 438.46% YoY from $1.3 million in Q1 2025.
Vireo Growth (VREOF) Share-based Compensation (2020 - 2026) Analysis & Trends
Vireo Growth has reported Share-based Compensation for 7 years, with the latest figure at $7.0 million in Q1 2026.
- Quarterly Share-based Compensation rose 438.46% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.8 million (up 171.97% YoY) and the FY2025 annual result came in at $12.9 million, up 265.96% from the prior year.
- Share-based Compensation advanced to $7.0 million in Q1 2026 per VREOF's latest filing, from $3.5 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $7.0 million in Q1 2026 and troughed at -$60751.0 in Q2 2024.
- A 5-year average of $1.1 million and a median of $272259.5 in 2022 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 16205.1% in 2024, down 132.21% in 2024.
- Over 5 years, Share-based Compensation stood at $248629.0 in 2022, then sank by 40.4% to $148183.0 in 2023, then jumped by 1326.37% to $2.1 million in 2024, then surged by 64.87% to $3.5 million in 2025, then surged by 100.87% to $7.0 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $7.0 million, $3.5 million, and $121976.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Vireo Growth | 487.39 Mn | 345.09 Mn | 95.30 Mn | 2.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.00 Mn |
| Mar 31, 2026 | 7.00 Mn |
| Dec 31, 2025 | 3.48 Mn |
| Dec 31, 2025 | 3.48 Mn |
| Sep 30, 2025 | 121,976.00 |
| Sep 30, 2025 | 121,976.00 |
| Jun 30, 2025 | 185,345.00 |
| Jun 30, 2025 | 185,345.00 |
| Mar 31, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 2.11 Mn |
| Dec 31, 2024 | 2.11 Mn |
| Sep 30, 2024 | 615,215.00 |
| Sep 30, 2024 | 615,215.00 |
| Jun 30, 2024 | -60,751.00 |
| Jun 30, 2024 | -60,751.00 |
| Mar 31, 2024 | 179,789.00 |
| Mar 31, 2024 | 179,789.00 |
| Dec 31, 2023 | 148,183.00 |
| Dec 31, 2023 | 148,183.00 |